Deserpidine

Summary

Deserpidine (CHEMBL1200515) is an approved small molecule (ATC C02AA05); indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02AA05
• Indications: 1 condition
• Chemistry: 578.7 Da · C32H38N2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200515
Name	Deserpidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8550
ChEBI	CHEBI:27478
ATC	C02AA05
Molecular formula	C32H38N2O8
Molecular weight	578.7
InChIKey	CVBMAZKKCSYWQR-WCGOZPBSSA-N

SMILES: CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC

IUPAC name: methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

Also known as: Deserpidina, Deserpidine, Deserpidine component of enduronyl, Deserpidine component of oreticyl forte, Deserpidine, (-)-, Halmonyl, Harmonyl, NSC-72138, deserpidine, SID50113288, DESERPIDINE, SID144206199

Patent coverage: 872 distinct patent families (2,483 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,473 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Nuclear receptor ROR-gamma, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Menin/Histone-lysine N-methyltransferase MLL, Prostaglandin G/H synthase 2, Mu-type opioid receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, Melanocortin receptor 4.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.61	AC50	2449	nM	CHEMBL_ACT_25118254
P51450	5.15	Potency	7080	nM	CHEMBL_ACT_4070391
P51450	5.15	Potency	7080	nM	CHEMBL_ACT_4797769
MEN1	5.1	Potency	7943	nM	CHEMBL_ACT_3633640
OPRM1	5.08	AC50	8300	nM	CHEMBL_ACT_25157618
MC4R	5.07	AC50	8600	nM	CHEMBL_ACT_25184569

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).